{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:35:23Z","timestamp":1725496523456},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"DOI":"10.7759\/cureus.68576","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T01:21:53Z","timestamp":1725412913000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects"],"prefix":"10.7759","author":[{"given":"Rahman","family":"Ladak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bre-Anne","family":"Fifield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Hirmiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"Gutierrez C","year":"2011","unstructured":"Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011, 135:55-62. 10.5858\/2010-0454-RAR.1","journal-title":"Arch Pathol Lab Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2020.21.12.3587","article-title":"Different breast cancer subtypes show different metastatic patterns: a study from a large public database","volume":"21","author":"Guo Y","year":"2020","unstructured":"Guo Y, Arciero CA, Jiang R, Behera M, Peng L, Li X. Different breast cancer subtypes show different metastatic patterns: a study from a large public database. Asian Pac J Cancer Prev. 2020, 21:3587-93. 10.31557\/APJCP.2020.21.12.3587","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.01.017","article-title":"Epidemiology of de novo metastatic breast cancer","volume":"21","author":"Daily K","year":"2021","unstructured":"Daily K, Douglas E, Romitti PA, Thomas A. Epidemiology of de novo metastatic breast cancer. Clin Breast Cancer. 2021, 21:302-8. 10.1016\/j.clbc.2021.01.017","journal-title":"Clin Breast Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0429-6","article-title":"Long-term survivor with intrathecal and intravenous trastuzumab treatment in metastatic breast cancer","volume":"11","author":"Pluchart H","year":"2016","unstructured":"Pluchart H, Jacquet E, Charlety D, Allenet B, Bedouch P, Mousseau M. Long-term survivor with intrathecal and intravenous trastuzumab treatment in metastatic breast cancer. Target Oncol. 2016, 11:687-91. 10.1007\/s11523-016-0429-6","journal-title":"Target Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1495","article-title":"Long-responders to anti-HER2 therapies: a case report and review of the literature","volume":"8","author":"Cantini L","year":"2018","unstructured":"Cantini L, Pistelli M, Savini A, et al.. Long-responders to anti-HER2 therapies: a case report and review of the literature. Mol Clin Oncol. 2018, 8:147-52. 10.3892\/mco.2017.1495","journal-title":"Mol Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.462","article-title":"Long-term survival after resection of HER2+ infiltrating ductal carcinoma metastasis to the brainstem","volume":"8","author":"Awad AW","year":"2016","unstructured":"Awad AW, Zaidi HA, Awad AH, Spetzler R. Long-term survival after resection of HER2+ infiltrating ductal carcinoma metastasis to the brainstem. Cureus. 2016, 8:e462. 10.7759\/cureus.462","journal-title":"Cureus"},{"key":"ref7","article-title":"Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer","volume":"35","author":"Suzuki Y","year":"2010","unstructured":"Suzuki Y, Saito Y, Terao M, et al.. Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer. Tokai J Exp Clin Med. 2010, 35:148-51.","journal-title":"Tokai J Exp Clin Med"},{"key":"ref8","article-title":"[Long-term survival of a patient with giant liver metastatic breast cancer treated with trastuzumab]","volume":"39","author":"Okada N","year":"2012","unstructured":"Okada N, Narita Y, Nanno Y, et al.. [Long-term survival of a patient with giant liver metastatic breast cancer treated with trastuzumab]. Gan To Kagaku Ryoho. 2012, 39:1399-402.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2017.715","article-title":"Bone metastasis risk factors in breast cancer","volume":"11","author":"Pulido C","year":"2017","unstructured":"Pulido C, Vendrell I, Ferreira AR, Casimiro S, Mansinho A, Alho I, Costa L. Bone metastasis risk factors in breast cancer. Ecancermedicalscience. 2017, 11:715. 10.3332\/ecancer.2017.715","journal-title":"Ecancermedicalscience"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02222","article-title":"Novel prognostic staging system for patients with de novo metastatic breast cancer","volume":"41","author":"Plichta JK","year":"2023","unstructured":"Plichta JK, Thomas SM, Hayes DF, et al.. Novel prognostic staging system for patients with de novo metastatic breast cancer. J Clin Oncol. 2023, 41:2546-60. 10.1200\/JCO.22.02222","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S369910","article-title":"Clinical characteristics, prognostic factors and treatment outcomes of patients with bone-only metastatic breast cancer","volume":"14","author":"Marie L","year":"2022","unstructured":"Marie L, Braik D, Abdel-Razeq N, Abu-Fares H, Al-Thunaibat A, Abdel-Razeq H. Clinical characteristics, prognostic factors and treatment outcomes of patients with bone-only metastatic breast cancer. Cancer Manag Res. 2022, 14:2519-31. 10.2147\/CMAR.S369910","journal-title":"Cancer Manag Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160230","article-title":"RANKL\/RANK: from bone loss to the prevention of breast cancer","volume":"6","author":"Sigl V","year":"2016","unstructured":"Sigl V, Jones LP, Penninger JM. RANKL\/RANK: from bone loss to the prevention of breast cancer. Open Biol. 2016, 6:160230. 10.1098\/rsob.160230","journal-title":"Open Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00076","article-title":"RANKL\/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies","volume":"8","author":"Wu X","year":"2020","unstructured":"Wu X, Li F, Dang L, Liang C, Lu A, Zhang G. RANKL\/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies. Front Cell Dev Biol. 2020, 8:76. 10.3389\/fcell.2020.00076","journal-title":"Front Cell Dev Biol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.332","article-title":"Prospects of adjuvant RANKL inhibition in breast cancer?","volume":"6","author":"Rachner TD","year":"2015","unstructured":"Rachner TD, Wimberger P, Hofbauer LC. Prospects of adjuvant RANKL inhibition in breast cancer?. Cell Death Dis. 2015, 6:e1982. 10.1038\/cddis.2015.332","journal-title":"Cell Death Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01390-2","article-title":"RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer","volume":"23","author":"Sanz-Moreno A","year":"2021","unstructured":"Sanz-Moreno A, Palomeras S, Pedersen K, et al.. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Breast Cancer Res. 2021, 23:42. 10.1186\/s13058-021-01390-2","journal-title":"Breast Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1226-9","article-title":"Combining RANK\/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas","volume":"21","author":"Zoi I","year":"2019","unstructured":"Zoi I, Karamouzis MV, Xingi E, et al.. Combining RANK\/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas. Breast Cancer Res. 2019, 21:132. 10.1186\/s13058-019-1226-9","journal-title":"Breast Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2011.487","article-title":"C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway","volume":"3","author":"Zhang L","year":"2012","unstructured":"Zhang L, Teng Y, Zhang Y, et al.. C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett. 2012, 3:395-400. 10.3892\/ol.2011.487","journal-title":"Oncol Lett"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2017.07.004","article-title":"RANK and EGFR in invasive breast carcinoma","volume":"216-217","author":"Papanastasiou AD","year":"2017","unstructured":"Papanastasiou AD, Sirinian C, Plakoula E, Zolota V, Zarkadis IK, Kalofonos HP. RANK and EGFR in invasive breast carcinoma. Cancer Genet. 2017, 216-217:61-6. 10.1016\/j.cancergen.2017.07.004","journal-title":"Cancer Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01716-y","article-title":"CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer","volume":"22","author":"Xing F","year":"2023","unstructured":"Xing F, Gao H, Chen G, et al.. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. Mol Cancer. 2023, 22:6. 10.1186\/s12943-023-01716-y","journal-title":"Mol Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/251386-long-term-survival-in-human-epidermal-growth-factor-receptor-2-positive-bone-only-metastatic-breast-cancer-trastuzumab-denosumab-and-potential-synergistic-effects","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T01:21:58Z","timestamp":1725412918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/251386-long-term-survival-in-human-epidermal-growth-factor-receptor-2-positive-bone-only-metastatic-breast-cancer-trastuzumab-denosumab-and-potential-synergistic-effects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.68576","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}